Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.17925/EE.2016.12.01.44 http://scihub22266oqcxt.onion/10.17925/EE.2016.12.01.44 C5813460!5813460!29632589     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 251.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 251.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+Endocrinol 2016 ; 12 (1): 44-6 Nephropedia Template TP {{tp|p=29632589|t=2016. New Developments in the Treatment of Neuroendocrine Tumours ? RADIANT-4, NETTER-1 and Telotristat Etiprate |pdf=|usr=}}{{29632589}} gab.com Text New Developments in the Treatment of Neuroendocrine Tumours RADIANT-4, NETTER-1 and Telotristat Etiprate JO: Eur Endocrinol http://www.kidney.de/pget.php?&tw=1&pmid=29632589 #FOAvip Neuroendocrine tumours (NETs) are a heterogeneous group of neoplasms whose incidence has increased significantly in recent years, and whose optimal management remains controversial. We report the latest innovations in their management, in particular the results of three trials concerning the use of the mammalian target of rapamycin (mTOR) inhibitor, everolimus, in non-functional NETs of lung/ gastrointestinal (GI) origin, the first randomised trial of radiolabelled 177Lu-DOTATATE in patients with mid-gut NETs, and the use of the 5-HT synthesis inhibitor, telotristat etiprate, in patients with the carcinoid syndrome. Twit Text FOAVip New Developments in the Treatment of Neuroendocrine Tumours RADIANT-4, NETTER-1 and Telotristat Etiprate ????Eur Endocrinol http://www.kidney.de/pget.php?&tw=1&pmid=29632589 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29632589 #FOAvip English Wikipedia <ref>{{Cite pmid|29632589}}</ref> New Developments in the Treatment of Neuroendocrine Tumours ? RADIANT-4, NETTER-1 and Telotristat Etiprate #MMPMID29632589 Sbardella E; Grossman A Eur Endocrinol 2016[Mar]; 12 (1): 44-6 PMID29632589show ga Neuroendocrine tumours (NETs) are a heterogeneous group of neoplasms whose incidence has increased significantly in recent years, and whose optimal management remains controversial. We report the latest innovations in their management, in particular the results of three trials concerning the use of the mammalian target of rapamycin (mTOR) inhibitor, everolimus, in non-functional NETs of lung/ gastrointestinal (GI) origin, the first randomised trial of radiolabelled 177Lu-DOTATATE in patients with mid-gut NETs, and the use of the 5-HT synthesis inhibitor, telotristat etiprate, in patients with the carcinoid syndrome. äNew Developments in the Treatment of Neuroendocrine Tumours ? RADIANT-(epmc).pdf DeepDyve Pubget Overpricing